Snibe announced its 2022 Q3 report, the company achieved operating revenue of RMB 880 million, up 31.67% year-on-year; net profit attributable to shareholders of the listed company was RMB 355 million, up 49.72% year-on-year.

As of the close of business on October 20, 2022, Snibe (300832) closed at 59.3 CNY, up 6.85%, with a turnover of 6.51%, a volume of 184,900 lots and a turnover of 1.08 billion CNY. In terms of fund flow data, the net outflow of main funds on October 20 was 55,268,600 CNY, the net inflow of lobbyist funds was 74,018,400 CNY, and the net outflow of retail funds was 18,749,700 CNY.

According to the last five years of earnings data, it shows that Snibe (300832) has an excellent moat of competitiveness in the industry, excellent profitability. The stock has a 4-star index for Good Company Indicator, a 2.5-star index for Good Price Indicator and a 3-star index for Composite Indicator. (Indicator is for reference only, indicator range: 0 ~ 5 stars, maximum 5 stars) The stock has been rated by 11 institutions in the last 90 days, with 9 buy ratings and 2 hold ratings; the average institutional target price in the last 90 days is 50.88.

About Snibe：

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Briefed as Snibe Co.,Ltd.) is located in National Biological Industry Park(Shenzhen, China), founded in December 1995. Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. Snibe has formed a strong team of professionals: Reagents R & D and production center, Instruments R & D and production center, Sales & Marketing center.